On 2025-07-31, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Leqvio (inclisiran). This approval, designated NDA 214012 S-16, specifically pertains to the efficacy class of the drug.
Background
Inclisiran, marketed as Leqvio by Novartis, is a previously approved medication. Supplemental applications typically address changes or additions to an approved drug's information, such as new indications, dosing, or, in this case, updated efficacy data.
What this means
The FDA's approval of this supplemental application for Leqvio (inclisiran) specifically addresses the drug's efficacy class. This type of approval typically signifies that new data or analyses have been submitted and reviewed by the FDA, leading to an update or refinement of the information regarding how effective the drug is. For healthcare professionals, this could translate into updated prescribing information, potentially clarifying the drug's benefits in certain patient populations, or providing additional evidence supporting its use. Such updates are crucial for ensuring that clinicians have the most current and comprehensive understanding of Leqvio's performance and appropriate application in patient care.
Source
The information for this update was sourced from the U.S. Food and Drug Administration (FDA) on 2025-07-31. The specific details regarding the supplemental application (NDA 214012 S-16) for Leqvio (inclisiran) are available on the accessdata.fda.gov website.